A majority of an FDA advisory panel believes the agency should update the label for the breast cancer drug tamoxifen to include information about CYP2D6 genotype testing, but the panelists have not reached a consensus on certain details of the issue.
 
Specifically, the FDA’s Pharmaceutical Science Clinical Pharmacology Subcommittee, which met Oct. 18, was split over whether the label should “recommend” the genetic test or make it an “option” for health care providers and patients to discuss.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.